DMRA Damora Therapeutics, Inc.
$28.10▲ +4.69%
Healthcare
Other
After hours
$28.10▲ +0.00%
Sep 11, 7:30 PM ET
Volume 525.4K
Avg Volume (10D) 409.9K
Key Metrics & Fundamentals
Market Cap
$1.73B
P/E Ratio
–
Div Yield
–%
52W Range
2.53 - 38.33
% vs 50 MA
-5.69%
% vs 200 MA
7.14%
RSI-14
45.8
MACD Histogram
-0.3200
Beta (1Y vs SPY)
2.13
Free Cash Flow
-$21.87M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$35.00M
COGS
–
Operating Exp
$34.99M
Operating Income
-$34.99M
EBIT
-$34.99M
Pretax Income
-$30.92M
Net Income
-$31.17M
EPS (Diluted)
-0.39
Price & Volume History
Loading chart…
Recent News
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 12:00 PM
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · Aug 10, 2026 8:05 PM
Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis
MT Newswires · Aug 5, 2026 2:42 PM
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
GlobeNewswire · Aug 5, 2026 12:00 PM
Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating
MT Newswires · Jul 29, 2026 2:34 PM
Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target
MT Newswires · Jul 27, 2026 12:28 PM
Damora Therapeutics Completes Redomestication to Cayman Islands
MT Newswires · Jul 17, 2026 5:26 PM
Damora Announces Redomestication from Delaware to Cayman Islands
GlobeNewswire · Jul 17, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See DMRA's money flow as a full page
Social Sentiment
No Reddit posts found for DMRA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.